studi
manag
lung
diseas
concern
allergistimmunologist
pulmonologist
common
chronic
lung
diseas
asthma
immunolog
basi
mani
lung
diseas
span
vast
clinic
spectrum
lung
disord
rang
infecti
lung
diseas
cancer
sever
signific
challeng
area
includ
diagnosi
treatment
certain
specif
infecti
lung
diseas
includ
viral
lower
respiratori
infect
caus
respiratori
syncyti
viru
rhinoviru
metapneumoviru
coronoviru
enteroviru
sever
acut
respiratori
syndrom
sar
coronaviru
sarscoa
respons
outbreak
sever
acut
respiratori
syndrom
earli
origin
asia
led
signific
mortal
afflict
virus
bird
flu
swine
flu
abil
caus
respiratori
tract
diseas
well
tuberculosi
anoth
primarili
respiratori
infect
resist
erad
new
strain
multidrugresist
tuberculosi
emerg
challeng
involv
genet
diseas
cystic
fibrosi
defici
autoimmun
lung
diseas
lung
diseas
part
system
autoimmun
diseas
chronic
obstruct
pulmonari
diseas
copd
diagnosi
treatment
hypersensit
pneumon
still
pose
problem
clinician
biomark
continu
develop
lung
cancer
research
need
genet
cystic
fibrosi
well
elucid
develop
success
gene
therapi
unexpectedli
slow
tabl
mani
condit
still
expect
ongo
develop
new
wave
molecular
biolog
techniqu
coupl
computer
autom
analysi
provid
transcript
signatur
help
identifi
differ
patient
diseas
spur
develop
relev
effect
treatment
subsequ
discuss
take
interest
challeng
issu
respiratori
diseas
past
two
decad
focu
expect
futur
well
asthma
one
common
chronic
diseas
worldwid
estim
million
asthmat
worldwid
death
per
year
usa
million
asthmat
million
children
recent
mortal
rate
asthma
steadili
increas
past
year
mortal
rate
begun
stabil
perhap
even
declin
increas
incid
asthma
attribut
variou
theori
perhap
popular
hygien
hypothesi
attribut
rise
incid
reduc
rate
infecti
diseas
cleaner
live
environ
gener
featur
accompani
higher
standard
live
convers
annual
death
rate
per
asthmat
tend
higher
econom
poorer
countri
emphas
signific
global
concern
regard
asthma
care
access
care
medic
develop
countri
problem
less
preval
countri
usa
primarili
focus
asthma
educ
complianc
issu
situat
sever
asthma
still
problem
impact
qualiti
life
still
contribut
consider
morbid
mortal
one
problem
sever
asthma
relat
defin
diseas
asthma
inher
heterogen
mani
phenotyp
sever
asthma
describ
increasingli
clear
singl
medic
work
patient
sever
asthma
patient
complianc
issu
frequent
fall
trap
believ
problem
alway
patient
complianc
fact
may
patient
take
medic
perceiv
work
nevertheless
explos
growth
avail
new
pharmaceut
intervent
provid
us
arsen
control
medic
least
develop
world
medic
develop
everi
day
includ
newer
class
biolog
modul
cytokin
chemokin
next
challeng
involv
identif
suitabl
patient
new
exist
treatment
done
research
year
attempt
defin
asthma
phenotyp
tri
categor
asthma
patient
base
demograph
clinic
characterist
attempt
defin
certain
patient
group
certain
preferenti
treatment
gener
led
confus
differ
research
group
necessarili
come
classif
moreov
asthma
children
also
significantli
differ
adult
respons
medic
vari
base
multipl
singl
factor
choic
exclus
confound
variabl
thorn
side
attempt
defin
specif
asthma
phenotyp
also
found
specif
childhood
asthma
phenotyp
develop
specif
adult
asthma
phenotyp
concept
asthma
endotyp
subject
much
research
endotyp
address
underli
mechan
diseas
howev
also
confus
highli
redund
inflammatori
pathway
lead
diseas
use
biomark
identifi
patient
high
risk
sever
lifethreaten
exacerb
entir
fruit
recent
commerci
introduct
fraction
exhal
nitric
oxid
feno
identifi
patient
eosinophil
inflamm
potenti
use
tool
need
guid
treatment
identif
gene
asthma
reveal
complex
one
might
expect
gene
attribut
asthma
like
candid
includ
filaggrin
moreov
exist
share
gene
asthma
comorbid
condit
obes
also
demonstr
ultim
asthma
like
mani
diseas
heterogen
diseas
mani
phenotyp
endotyp
one
singl
treatment
fit
art
medicin
may
find
right
peg
correspond
hole
twentyfirst
centuri
usher
concept
person
genom
medicin
util
advanc
molecular
biolog
proteom
metabolom
genom
identifi
optim
therapi
individu
patient
year
sinc
identif
gene
respons
cystic
fibrosi
cf
initi
studi
describ
gene
name
cystic
fibrosi
transmembran
conduct
receptor
cftr
first
publish
late
tsui
et
al
discoveri
led
local
gene
chromosom
lead
widespread
belief
cure
cf
util
gene
therapi
right
around
corner
landmark
develop
molecular
biolog
techniqu
becam
known
genet
target
mice
pioneer
capecchi
evan
smithi
promis
gene
replac
human
similar
way
perform
mice
twentyfour
year
later
new
advanc
manag
cystic
fibrosi
regard
pharmacolog
support
respiratori
treatment
still
cure
advanc
prolong
longev
patient
cf
life
expect
still
averag
year
happen
gene
therapi
happen
promis
buoy
cystic
fibrosi
commun
back
idea
behind
gene
therapi
introduc
miss
malfunct
gene
cell
patient
use
harmless
viru
manufactur
carri
normal
copi
diseas
gene
techniqu
either
target
cell
global
restrict
certain
group
locat
cell
gene
therapi
progress
smoothli
quickli
anticip
previous
unrecogn
barrier
becam
appar
includ
fact
studi
initi
focus
molecular
biochem
outcom
clinic
efficaci
moreov
administr
gene
would
need
repeat
due
epitheli
turnov
repeat
administr
lead
host
recognit
may
inhibit
gene
express
question
cell
target
order
achiev
efficaci
slow
research
use
viral
materi
includ
viral
dna
liposom
could
potenti
lead
inflammatori
respons
point
unexpect
consequ
discov
research
proceed
impact
progress
gene
research
group
british
investig
began
largescal
trial
gene
therapi
deliv
encompass
gene
fat
globul
deliv
gene
nebul
futur
methodolog
util
viral
deliveri
strategi
still
sever
year
futur
gene
therapi
cystic
fibrosi
dead
certainli
move
far
slower
pace
origin
expect
current
treatment
cur
cystic
fibrosi
gene
therapi
stem
cell
transplant
two
techniqu
still
investig
may
turn
certain
mutat
may
candid
gene
therapi
mutat
cf
gene
fact
subclassifi
six
class
pathogen
physiolog
characterist
exampl
common
mutat
result
reduc
amount
cftr
channel
express
lead
exacerb
diseas
respiratori
syncyti
viru
infect
lower
respiratori
tract
caus
signific
morbid
mortal
infant
young
children
global
million
new
lower
respiratori
tract
infect
per
year
approxim
death
per
year
children
fewer
year
age
major
death
occur
lowincom
countri
access
care
may
limit
search
vaccin
respiratori
syncyti
viru
rsv
ongo
mani
year
like
previou
case
gene
therapi
cystic
fibrosi
also
challeng
achiev
absenc
vaccin
research
develop
passiv
immun
viru
form
monoclon
antibodi
rsv
name
palivizumab
current
global
strategi
develop
rsv
vaccin
target
four
area
infant
month
age
infant
month
age
young
children
pregnant
women
passiv
immun
implement
elderli
rsv
also
signific
morbid
main
challeng
prevent
develop
effect
vaccin
far
revolv
around
fact
even
natur
infect
rsv
provid
longterm
protect
reinfect
earlier
studi
actual
found
vaccin
may
actual
accentu
diseas
especi
young
infant
may
fulli
matur
immun
system
may
unabl
effect
engag
somat
mutat
lead
suboptim
b
cell
repertoir
may
also
appli
older
infant
young
children
may
still
rsvnaiv
issu
adult
opposit
adult
expos
rsv
thu
rsv
antibodi
effect
passiv
immun
pregnant
women
order
deliv
igg
across
placenta
fetu
must
weigh
possibl
advers
effect
vaccin
fetu
elderli
challeng
abil
boost
immun
activ
immun
individu
becom
immunosenesc
sever
vaccin
develop
program
pursu
varieti
vaccin
strategi
live
viru
vaccin
trial
shown
particular
vaccin
candid
safe
although
effect
proven
strategi
includ
subunit
rsv
vaccin
use
dnaconjug
vaccin
boost
antigen
present
develop
passiv
antibodi
prophylaxi
focus
f
g
protein
addit
challeng
strategi
effect
vaccin
studi
anim
translat
success
human
trial
tuberculosi
global
health
problem
tuberculosi
infect
caus
bacterium
mycobacterium
tuberculosi
primarili
affect
lung
also
affect
tissu
includ
bone
nervou
system
tuberculosi
believ
one
oldest
infect
reportedli
affect
mankind
archeolog
anthropolog
studi
show
evid
infect
human
year
ago
continu
top
chart
mortal
morbid
develop
nation
estim
million
new
case
tb
well
preval
million
million
death
tb
patient
without
hiv
death
patient
hiv
shock
statist
show
far
come
yet
far
still
effect
erad
diseas
two
effect
drug
develop
treat
tuberculosi
isoniazid
inh
rifampin
howev
tuberculosi
continu
global
health
problem
tuberculosi
second
hivaid
infect
highest
mortal
global
recent
increas
multipl
drugresist
tuberculosi
mdrtb
observ
case
india
china
russia
report
case
mdrtb
world
estim
fall
categori
xdrtb
even
resist
form
thu
drug
resist
signific
challeng
treatment
tb
twentyfirst
centuri
anoth
challeng
stem
fact
one
third
patient
hivaid
infect
tb
although
mani
may
yet
symptomat
defin
six
core
function
six
strateg
approach
combat
tb
tabl
overal
tb
case
occur
countri
case
occur
china
howev
overal
healthcar
access
technolog
improv
signific
declin
rate
tb
asian
countri
includ
cambodia
china
disput
dot
stop
tb
strategi
outlin
tabl
contribut
signific
progress
control
tb
signific
challeng
remain
one
area
focus
identif
biomark
biomark
play
sever
role
improv
treatment
tb
world
main
area
focu
research
biomark
identifi
perform
follow
function
predict
cur
state
predict
reactiv
tb
predict
immun
tb
past
biomark
tb
would
normal
involv
cultur
organ
develop
molecular
biolog
techniqu
afford
us
use
noncultur
biomark
type
approach
describ
walli
et
al
categor
biomark
develop
function
categori
tabl
noncultur
biomark
includ
cytokin
level
quantifi
genet
measur
presenc
tb
serolog
test
imag
techniqu
gene
transcript
profil
microrna
profil
develop
vaccin
ongo
challeng
quest
cure
tb
limit
studi
includ
lack
valid
biomark
assess
protect
clinic
trial
cytokin
studi
biomark
latent
tb
infect
tuberculosisstimul
releas
assay
detect
sensit
tb
antigen
unfortun
differenti
resolv
persist
latent
infect
marker
innat
immun
elev
level
plasma
interleukin
level
seen
tb
patient
indic
increas
activ
innat
immun
observ
control
chemokin
observ
elev
tb
level
apoptosi
inhibitor
express
reduc
level
actual
correl
radiograph
extent
diseas
hiv
appear
also
modifi
cytokin
product
patient
tb
cytokin
chemokin
profil
potenti
biomark
tb
diseas
activ
although
date
none
shown
use
widespread
clinic
applic
fifti
year
ago
introduct
pyrazinamid
rifampicin
reduc
durat
therapi
month
month
valu
biomark
may
reflect
implic
abl
predict
cure
latenc
infect
well
activ
infect
therapeut
standpoint
may
mean
differ
current
regimen
month
treatment
versu
possibl
reduct
durat
therapi
certain
patient
group
depend
biomark
significantli
accur
lead
inadequ
treatment
affect
individu
though
half
centuri
pass
sinc
develop
effect
treatment
drugsuscept
tb
period
treatment
still
least
month
standard
therapi
ie
rifampicin
isoniazid
month
pyrazinamd
ethambutol
initi
month
treatment
effort
reduc
length
treatment
depend
discoveri
effect
treatment
well
abl
monitor
treatment
time
patient
tb
demonstr
multipl
drug
resist
form
includ
mdr
xdr
tb
addit
secondlin
drug
treatment
difficult
treat
patient
plagu
longer
period
treatment
higher
cost
reduc
efficaci
drug
often
use
secondlin
treatment
includ
aminoglycosid
terizidon
protionamid
capreomycin
fluroquinolon
cycloserin
ethionamid
mortal
mdr
xdr
tb
hiv
patient
particularli
high
research
focus
novel
approach
combat
global
health
issu
includ
revamp
effort
develop
vaccin
tb
treatment
latent
infect
reduc
reservoir
pool
infect
develop
predict
biomark
one
forget
year
vaccin
tb
bcg
vaccin
name
albert
calmett
camil
guerin
vaccin
use
primarili
underdevelop
countri
administ
billion
peopl
worldwid
limit
includ
inabl
protect
adult
tb
advers
effect
use
hivposit
tb
patient
research
ongo
develop
improv
replac
enhanc
vaccin
bcg
therefor
develop
new
biomark
new
treatment
strategi
one
rememb
infect
landscap
tb
static
target
either
emerg
multidrugresist
strain
mention
mean
diseas
may
becom
difficult
treat
develop
biomark
must
take
new
medic
use
consider
moreov
develop
biomark
requir
avail
larg
patient
sampl
found
biobank
larg
highvolum
treatment
center
willing
patient
contribut
research
regulatori
landscap
collect
sampl
research
could
potenti
neg
impact
abil
conduct
largescal
studi
biomark
comprehens
review
biomark
diagnost
drug
treatment
vaccin
develop
reader
refer
excel
seri
articl
publish
lancet
incid
pertussi
appear
increas
past
year
trend
fli
face
avail
first
kill
whole
organ
pertussi
vaccin
dtwp
subsequ
acellular
vaccin
dpap
acellular
vaccin
less
reactogen
incorpor
step
manufactur
remov
endotoxin
major
reason
advers
side
effect
profil
clear
vaccin
pertussi
afford
much
improv
prevent
diseas
illustr
decreas
rate
pertussi
dtwp
vaccin
use
technolog
develop
led
introduct
commerci
avail
acellular
pertussi
vaccin
continu
increas
pertussi
case
lead
obviou
question
failur
immun
program
earlier
discuss
sever
exampl
illustr
difficulti
bring
effect
vaccin
market
tb
rsv
problem
associ
pertussi
clearli
differ
sever
reason
may
explain
erad
diseas
well
document
dtap
vaccin
immunogen
whole
organ
dtwp
vaccin
studi
indic
overal
efficaci
dtap
vaccin
normal
test
pertussi
titer
follow
vaccin
except
studi
suggest
increas
pertussi
case
mainli
due
increas
abil
diagnos
diseas
increas
awar
yet
anoth
challeng
may
pertussi
mutat
year
render
vaccin
less
effect
current
vaccin
effect
abil
mutant
strain
evad
destruct
would
lead
preferenti
surviv
shown
pertussi
vaccin
contain
antigen
fivecompon
vaccin
contain
pertussi
toxin
pt
filament
hemagglutinin
fha
pertactin
prn
fimbria
fim
superior
contain
fewer
antigen
also
becom
appar
balanc
antigen
vaccin
may
play
role
determin
efficaci
exampl
wholecel
pertussi
vaccin
antigen
compon
pt
fha
fim
compar
acellular
pertussi
vaccin
children
wholecel
vaccin
produc
high
level
antibodi
prn
fim
low
level
pt
fha
contrast
acellular
pertussi
vaccin
produc
high
level
antibodi
pt
fha
one
studi
suggest
vaccin
compon
may
antagon
found
antibodi
level
fha
correl
efficaci
vaccin
furthermor
suggest
ad
fha
vaccin
may
actual
suppress
efficaci
link
epitop
suppress
anoth
concept
explain
failur
pertussi
vaccin
one
would
expect
presenc
antigen
deliv
brisk
vaccin
respons
affect
respons
vaccin
antigen
may
case
linkag
suppress
two
epitop
pertussi
vaccin
could
signific
consider
vaccin
design
one
would
need
exclud
certain
antigen
vaccin
compon
mix
suffic
say
vaccin
develop
complex
topic
involv
variou
techniqu
includ
use
classic
adjuv
aluminum
salt
emuls
liposom
novel
adjuv
tolllikereceptor
agonist
saponin
immun
stimul
complex
one
discuss
challeng
pertussi
without
comment
fear
immun
held
mani
famili
even
develop
countri
usa
refus
mani
parent
immun
children
whatev
reason
may
play
signific
role
inabl
erad
sever
diseas
includ
pertussi
measl
rubella
phenomenon
limit
uneduc
popul
mani
highli
educ
individu
appear
choos
subject
children
rel
miniscul
real
imagin
risk
immun
certainli
one
astronom
higher
risk
kill
car
accid
die
vaccin
yet
peopl
refus
vaccin
children
stop
drive
ride
car
problem
achiev
herd
immun
import
total
erad
mean
small
portion
popul
immun
children
still
possibl
erad
diseas
peopl
choos
remain
unimmun
likelihood
success
erad
becom
less
less
unfortun
peopl
choos
remain
unimmun
fail
understand
order
everyon
get
immun
futur
case
smallpox
everyon
must
immun
present
sever
acut
respiratori
syndrom
sar
infect
reach
epidem
proport
earli
part
origin
china
rapidli
spread
neighbor
countri
eventu
report
mani
distant
nation
includ
europ
usa
although
number
case
far
fewer
sever
order
magnitud
common
flu
caught
attent
healthcar
profession
public
health
offic
high
mortal
case
death
report
mortal
rate
sar
later
identifi
caus
coronaviru
name
sarscoa
travel
histori
infect
peopl
instrument
trace
origin
diseas
viru
come
suddenli
caus
much
havoc
initi
may
viru
trace
civet
catlik
mammal
occasion
consum
food
chines
howev
creatur
eventu
dismiss
origin
sourc
lack
appear
infect
civet
reservoir
sarslik
virus
found
chines
horsesho
bat
often
brought
market
thought
viru
pass
human
time
phylogenet
studi
provid
evid
genet
like
sar
coronaviru
evolv
virus
infect
horsesho
bat
sar
happen
fact
smaller
outbreak
attract
much
attent
may
alreadi
occur
manner
mimic
sar
middl
east
respiratori
syndrom
mer
report
also
caus
coronaviru
mortal
case
high
well
case
mer
also
thought
origin
bat
interestingli
mani
virus
thought
transmit
bat
includ
ebola
hendra
rabi
cellular
receptor
mer
dipeptidyl
peptidas
lesson
learn
sar
epidem
includ
fact
transmiss
often
facilit
medic
worker
tri
save
patient
strict
infect
control
measur
critic
limit
spread
diseas
includ
use
neg
pressur
room
mask
gown
optim
dose
antivir
medic
time
support
measur
respiratori
care
still
unknown
previou
experi
guid
us
vigil
ever
occur
largescal
fashion
futur
antineutrophil
cytoplasm
antibodi
anca
discov
antigen
target
anca
includ
myeloperoxidas
antibodi
antigen
long
time
refer
panca
canca
respect
p
c
indic
cellular
stain
pattern
perinuclear
cytoplasm
latter
nomenclatur
sinc
discourag
antibodi
refer
context
specif
antigen
target
understand
pathogenesi
ancaassoci
vascul
aav
would
help
develop
effect
drug
treat
group
diseas
includ
granulomatosi
polyangi
formerli
wegen
granulomatosi
eosinophil
granulomatosi
polyangi
egpa
diseas
microscop
polyangi
toxinmedi
aav
metaanalysi
shown
link
crystallin
silica
aav
silica
inflammasom
activ
believ
trigger
activ
proinflammatori
cytokin
lead
diseas
trigger
includ
drug
commonli
hydralazin
propylthiouracil
penicillamin
known
stimul
b
lymphocyt
activ
infecti
trigger
staphylococcu
aureu
avoid
exposur
may
prove
use
methodolog
prevent
diseas
time
trigger
aav
divers
controversi
recommend
particular
avoid
strategi
anoth
diseas
state
affect
million
perhap
billion
peopl
worldwid
allergi
allergi
affect
respiratori
tract
take
form
allerg
asthma
simpli
allerg
rhiniti
conjunct
hygien
hypothesi
would
indic
cleaner
live
environ
develop
higher
rate
sensit
common
allergen
indoor
outdoor
well
higher
rate
autoimmun
diseas
one
main
avenu
treatment
alway
avoid
realli
abl
defin
exactli
constitut
effect
avoid
mani
studi
done
dust
mite
anim
dander
avoid
abl
identifi
singl
avoid
measur
make
signific
impact
outcom
although
perhap
comprehens
avoid
plan
may
provid
relief
studi
need
determin
whether
inde
effect
avoid
possibl
face
indoor
outdoor
exposur
allergen
extent
avoid
allergen
possibl
provid
signific
benefit
patient
diagnosi
manag
respiratori
diseas
plagu
numer
unmet
need
affect
common
diseas
asthma
uncommon
occurr
sar
problem
common
ultim
involv
improv
understand
mechan
diseas
develop
tool
help
us
manag
patient
advent
molecular
biolog
allow
us
develop
genet
analys
patient
led
realiz
diseas
frequent
one
diseas
mani
thu
genom
person
medicin
act
import
legislatur
hope
divert
increas
fund
studi
help
us
identifi
treatment
optim
use
patient
understand
pathogenesi
diseas
anoth
signific
unmet
need
requir
commit
fund
resourc
respect
contributori
role
gene
epigenet
environ
pathogenesi
lung
diseas
must
better
elucid
better
understand
diseas
come
better
diagnost
marker
better
treatment
unmet
need
circl
around
avail
biomark
diagnos
diseas
vaccin
novel
treatment
manag
diseas
new
techniqu
vaccin
hope
allevi
concern
vaccin
among
vaccineapprehens
patient
may
help
lead
erad
infecti
respiratori
diseas
tb
pertussi
rsv
much
work
yet
done
import
rememb
diseas
static
either
especi
context
pathogenrel
diseas
pathogen
also
adept
evad
effort
destroy
challeng
outlin
articl
far
comprehens
specif
unmet
need
exist
varieti
respiratori
diseas
includ
defici
hypersensit
pneumon
chronic
obstruct
pulmonari
diseas
lung
cancer
pulmonari
hypertens
newborn
other
diseas
state
may
uniqu
set
challeng
gener
one
categor
three
major
area
need
name
diagnosi
treatment
prevent
fig
specif
would
includ
identif
biomark
provid
less
invas
method
diagnosi
monitor
diseas
well
determin
prognosi
develop
new
drug
treatment
modal
also
develop
vaccin
environment
control
reduc
incid
diseas
